tert-butyl 4-(2,4-difluorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate | 924275-11-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(2,4-difluorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: tert-butyl 4-(2,4-difluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 924275-11-6
• 化学式: C₁₆H₁₉F₂NO₂
• 分子量: 295.329
• InChiKey: MCMIZOOAGAIJQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2,4-difluorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以74%的产率得到
  参考文献：
  名称：

  Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against β-secretase-1 (BACE-1)

  摘要：

  A series of unique bicyclic aminooxazolines were synthesized and found to exhibit micromolar inhibition of beta-secretase-1 (BACE-1). The aminooxazolines were procured by an intramolecular diethylaminosulfur trifluoride (DAST)-mediated ring closure of a benzylic urea onto a secondary alcohol. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.07.136
• 作为产物：
  描述：

  1-溴-2,4-二氟苯 、 N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以78%的产率得到tert-butyl 4-(2,4-difluorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against β-secretase-1 (BACE-1)

  摘要：

  A series of unique bicyclic aminooxazolines were synthesized and found to exhibit micromolar inhibition of beta-secretase-1 (BACE-1). The aminooxazolines were procured by an intramolecular diethylaminosulfur trifluoride (DAST)-mediated ring closure of a benzylic urea onto a secondary alcohol. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.07.136

文献信息

• Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
  申请人：Isaac Methvin

  公开号：US20070032469A1

  公开（公告）日：2007-02-08

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了一个式(I)的化合物或其药用盐：其中R1、R2、R3、A、B、D、m、n、x和y的定义如规范中所述。该发明还提供了一种包含式I化合物的药用组合物，以及使用该组合物来治疗或预防神经学和精神疾病的方法。这些化合物在与mGluR2受体介导的疾病的治疗或预防相关的治疗中是有用的。
• Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
  申请人：Isaac Methvin

  公开号：US20080318999A1

  公开（公告）日：2008-12-25

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了式（I）的化合物或其药学上可接受的盐：其中，R1、R2、R3、A、B、D、m、n、x和y的定义如规范所述。此外，该发明还提供了包括式I的药学组合物，以及使用该组合物治疗或预防神经系统和精神疾病的方法。这些化合物在治疗或预防mGluR2受体介导的疾病的相关治疗中是有用的。
• [EN] TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] BENZIMIDAZOLES TRICYCLIQUES ET LEUR UTILISATION COMME MODULATEURS DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2007018998A2

  公开（公告）日：2007-02-15

  [EN] The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R¹, R², R³, A, B, D, m, n, x, andy are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula (I), together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
  [FR] L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de ce dernier, formule dans laquelle R¹, R², R³, A, B, D, m, n,x et y sont tels que définis dans la spécification. Cette invention concerne également une composition pharmaceutique comprenant le composé de formule (I) ainsi qu'une méthode d'utilisation de ladite composition pour traiter ou prévenir des troubles neurologiques et psychiatriques. Ces composés sont utiles en thérapie associée au traitement ou à la prévention de troubles médiés par le récepteur mGluR2.
• Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against β-secretase-1 (BACE-1)
  作者：Malcolm P. Huestis、Wendy Liu、Matthew Volgraf、Hans E. Purkey、Christine Yu、Weiru Wang、Darin Smith、Guy Vigers、Darrin Dutcher、Kevin W. Hunt、Michael Siu

  DOI：10.1016/j.tetlet.2013.07.136

  日期：2013.10

  A series of unique bicyclic aminooxazolines were synthesized and found to exhibit micromolar inhibition of beta-secretase-1 (BACE-1). The aminooxazolines were procured by an intramolecular diethylaminosulfur trifluoride (DAST)-mediated ring closure of a benzylic urea onto a secondary alcohol. (c) 2013 Elsevier Ltd. All rights reserved.